Meeting
2023 ASCO Annual Meeting
A phase 1 dose-escalation and expansion study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, given as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer.
Authors
Christine H. Chung
Moffitt Cancer Center, Tampa, FL
Christine H. Chung , A. Dimitrios Dimitrios Colevas , Douglas Adkins , Cristina P. Rodriguez , Jong Chul Park , Michael K. Gibson , Barbara Burtness , Faye M. Johnson , Ricklie Ann Julian , Nabil F. Saba , Francis P. Worden , Lara Dunn , Tanguy Y. Seiwert , Robert M. Jotte , Julie E. Bauman , Marya F. Chaney , Steven Margossian , Matteo Levisetti , Sara I. Pai
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
Clinical trial information: NCT03978689
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 6013)
DOI
10.1200/JCO.2023.41.16_suppl.6013
Abstract #
6013
Poster Bd #
5
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A phase 1 dose-escalation and expansion study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, given alone and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer.
First Author: Christine H. Chung
Poster
2024 ASCO Annual Meeting
Phase 1 study of CTX-471, a novel CD137 agonist antibody, in patients with progressive disease following PD-1/PD-L1 inhibitors in metastatic or locally advanced malignancies.
First Author: Minal A. Barve
Poster
2024 ASCO Annual Meeting
Phase IIA study of high-affinity TCR-T (TAEST16001) targeting NY-ESO-1 in soft tissue sarcoma.
First Author: Jiayong Liu
Poster
2023 ASCO Annual Meeting
Phase 2 trial of three schedules of CUE-101 administered before surgery or chemoradiotherapy in HLA-A*0201 positive patients with HPV16+ OPSCC.
First Author: Jesse Meir Zaretsky